|
Hot Stocks
|
Kubient announced ad-tech… Kubient announced ad-tech industry veteran, Mitchell Berg has joined as the company's CTO. In this role, Berg will report directly to Paul Roberts, founder, chairman, CSO, and CEO. Berg adds more than 20 years of technology, engineering, and executive management experience to the Kubient team. Most recently, Berg served as CTO for Koddi. Under his leadership, Berg will further develop the company vision for its technology offerings, including Kubient's product, Kubient Artificial Intelligence, or KAI, as well as work closely with the company's data science team. ShowHide Related Items >><< - 08/17/21 Maxim
- Kubient price target lowered to $9 from $13 at Maxim
- 03/26/21 Maxim
- Kubient price target raised to $13 from $10 at Maxim
- 08/16/21
- Kubient reports Q2 GAAP EPS (12c), one estimate (20c)
|
|
Conference/Events
|
23rd Annual Global… 23rd Annual Global Investment Virtual Conference to be held on September 13-15.Webcast Link ShowHide Related Items >><< - 09/13/21
- Zynerba initiates RECONNECT Phase 3 trial of Zygel
- 09/09/21
- Zynerba presents data from Phase 2 BRIGHT trial for Zygel in children
- 09/07/21
- Zynerba announces publication of results of Phase 2 BELIEVE open-label study
- 08/09/21
- Zynerba sees cash, cash equivalents funding operations into H1 of 2024
- 08/30/21
- Ziopharm appoints Kevin Boyle as Chief Executive Officer, executive promotions
- 08/09/21
- Ziopharm closes ventured debt facility with Silicon Valley Bank for $50M
- 04/19/21
- Ziopharm announces first patient infused in CD19 RPM CAR-T Phase 1 trial
- 07/07/21
- Viveve announces new CPT code for its SUI procedure
- 04/01/21
- Viveve says TIPO issues patent for dual-energy technology device.
- 07/12/21
- Titan Medical appoints Stephen Lemieux as the CFO
- 05/28/21
- Titan Medical receives $10M license fee under Medtronic development agreement
- 05/24/21
- Titan Medical appoints Deepak Basra as VP, strategy and business development
TCON Tracon Pharmaceuticals - 08/09/21
- Tracon announce results of second IDMC review of ENVASARC
- 07/20/21
- Tracon appoints Brenda Marczi as SVP, regulatory affairs
- 06/30/21
- Tracon Pharmaceuticals announces appointment of Ya Huang as Executive Director
- 06/29/21
- Tracon Pharmaceuticals announces orphan drug designation for envafolimab
TARA Protara Therapeutics - 09/13/21
- Protara announces results from study on cholestasis in patients on PN
- 06/10/21
- Protara Therapeutics appoints Jane Huang to board of directors
- 04/23/21
- Protara to conduct additional clinical study for TARA-002 following FDA feedback
- 04/19/21
- Protara Therapeutics announces appointment of Olivo as Chief Medical Officer
SLRX Salarius Pharmaceuticals - 07/13/21
- Salarius adds Fox Chase Cancer Center to ongoing trial of seclidemstat
- 06/15/21
- Salarius Pharmaceuticals announces new clinical trial to study seclidemstat
- 06/07/21
- Salarius Pharmaceuticals presents research data on seclidemstat
- 09/13/21
- Super League Gaming, PRG form production partnership
- 08/12/21
- Super League Gaming established Young Gamer Network, Core Gamer Network
- 08/12/21
- Super League Gaming announces acquisition of Bannerfy
- 08/02/21
- Super League Gaming launches Pixel Paradise server
- 08/30/21
- Rubius Therapeutics appoints Jim Jogerst as CBO
- 08/09/21
- Rubius Therapeutics anticipated 2021 catalysts, objectives
- 07/29/21
- Rubius Therapeutics appoints Dannielle Appelhans as COO
- 07/15/21
- Rubius Therapeutics announces publication of RTX-240 preclinical data
- 09/14/21
- Point Biopharma and Convergent Therapeutics announce collaboration
- 07/21/21
- Point Biopharma, Isotopia announce Lutetium-177 clinical supply agreement
- 08/19/21
- Pulse Biosciences names Mitchell Levinson as Chief Strategy Officer
- 06/30/21
- Pulse Biosciences announces first CellFX procedure in Canada
- 06/09/21
- Pulse Biosciences announces Health Canada approval for CellFX System
- 09/13/21
- Lyra Therapeutics appoints Jason Cavalier as CFO
- 09/09/21
- Lyra Therapeutics announces preclinical XTreo data published
- 08/17/21
- Lyra Therapeutics to host virtual chronic thinosinusitis KOL event
- 06/30/21
- Lyra Therapeutics announce results of pharmacokinetic study of LYR-210
- 08/03/21
- Lumos Pharma announces David Karpf as Chief Medical Officer
- 08/02/21
- Lumos Pharma promotes John McKew to President
- 07/20/21
- Lumos Pharma provides clinical updates on OraGrowtH210, OraGrowtH212 trials
- 06/28/21
- Lumos Pharma announces OraGrowtH212 trial of LUM-201
- 09/13/21
- Leap Therapeutics announces DisTinGuish ORR data ahead of presentation
- 05/12/21
- Leap Therapeutics and Flagship Biosciences develop image analysis RNAscope assay
- 04/12/21
- Leap Therapeutics, Flagship Biosciences announce partnership
- 04/01/21
- Leap Therapeutics completes enrollment in first-line cohort of DKN-01 study
- 04/14/21
- Kubient appoints Leon Zemel as Chief Product Officer
- 08/06/21
- Imara sees cash, cash equivalents to fund operations through end of 2022
- 08/05/21
- Imara completes patient enrollment in Ardent Phase 2b trial of IMR-687
- 06/30/21
- Imara announce appointment of Laura Williams to board of directors
- 06/04/21
- Imara to present data on IMR-687 in SCD at EHA Annual Congress
- 08/11/21
- I-Mab's plonmarlimab shows positive results in severe COVID-19 treatment
- 07/30/21
- I-Mab's Protollin IND for Phase 1 study in Alzheimer's approved by FDA
- 07/29/21
- I-MAB announces new $40M stock repurchase program
- 07/28/21
- I-Mab: IND for Phase 2 trial of efineptakin alfa accepted by CDE of China
- 06/22/21
- Gemini reports initial data from ongoing Phase 2a study of GEM103
- 05/20/21
- NeuBase Therapeutics appoints Sandra Rojas-Caro as CMO
- 05/13/21
- Gemini Therapeutics completes enrollment in GEM103 trial
- 05/02/21
- Gemini Therapeutics presents preclinical data at ARVO
- 09/07/21
- Exelixis announces passing of Chief Medical Officer Gisela Schwab
- 08/25/21
- Exelixis partner Takeda and Ono get Japan approval for cabozantinib in RCC
- 08/16/21
- Exelixis, Invenra expand discovery and licensing collaboration by 20 targets
- 08/05/21
- Exelixis announces FDA acceptance of Cabometyx sNDA
- 09/14/21
- EDAP TMS announces multiple abstracts comparing HIFU to surgery
- 07/20/21
- EDAP TMS CEO says focused on expanding coverage for HIFU
- 06/15/21
- EDAP TMS announces appointment of Ryan Rhodes as CEO of company's subsidiary
- 03/29/21
- EDAP TMS trading resumes
DYAI Dyadic International - 08/11/21
- Sorrento, Dyadic enter binding term sheet for DYAI-100, C1 technology
- 08/11/21
- Dyadic, Sorrento announce binding term sheet to enter License Agreement
- 07/27/21
- Dyadic signs technology transfer, licensing agreement with Rubic Consortium
- 06/28/21
- Dyadic International C1 production platform utilized in ZAPI study
- 09/14/21
- Cinedigm appoints John Canning as CFO
- 09/07/21
- Cinedigm says The Film Detective acquires Holland Releasing's film, TV library
- 09/02/21
- Cinedigm receives Nasdaq notice of deficiency
- 08/23/21
- Cinedigm expands partnership with All3Media International
CGRN Capstone Green Energy - 09/10/21
- Capstone Green Energy distributor signs energy agreement
- 08/23/21
- Capstone Green Energy contracts remote data center in Louisiana
- 08/16/21
- Capstone Green Energy completes expansion at UK facility
- 07/28/21
- Capstone Green Energy wins multiple deals with wastewater treatment plants
- 09/13/21
- Bellus Health announces positive findings in SOOTHE trial of BLU-5937 in RCC
AGRI AgriFORCE Growing Systems - 09/09/21
- AgriFORCE Growing Systems signs MOU for product deployment in Barbados
- 07/22/21
- AgriFORCE appoints Troy McClellan as president, AgriFORCE Solutions
- 07/14/21
- AgriFORCE Growing Systems appoints Richard Levychin to board
- 07/13/21
- AgriFORCE Growing Systems appoints Amy Griffith to board of directors
- 09/13/21
- Twist, Adicet Bio enter collaboration to discover gamma delta T cell therapies
- 09/13/21
- Adicet Bio collaborates with Twist to accelerate cancer therapeutics
- 07/15/21
- Adicet Bio announces formation of Scientifc Advisory Board
- 06/28/21
- Adicet Bio added to Russell 2000 Index
- 08/09/21
- Acer Therapeutics, Relief announce submission of NDA to FDA for ACER-001
- 06/10/21
- Acer Therapeutics plans trial for EDSIVO following Type B FDA meeting
- 05/25/21
- Acer Therapeutics plans NDA submission of ACER-001 in Q3
- 03/22/21
- Acer Therapeutics and Relief in pact and licensing agreement for ACER-001
- 08/17/21
- Arbutus Biopharma up 7% as Forbes details background of COVID-19 vaccine tech
- 08/05/21
- Arbutus Biopharma expects cash to fund operations into Q3 of 2022
- 07/07/21
- Arbutus Biopharma receives authorization to proceed with AB-729 IND application
- 07/06/21
- Arbutus Biopharma and Vaccitech enter into trial collaboration agreement
- 06/28/21 JMP Securities
- Arbutus EASL updates still support progress in Chronic HBV, says JMP Securities
- 03/10/21 B. Riley
- Arbutus Biopharma price target lowered to $7 from $8 at B. Riley Securities
- 12/17/20 H.C. Wainwright
- Arbutus Biopharma initiated with a Buy at H.C. Wainwright
- 09/15/20 Chardan
- Arbutus HBV data 'could represent a turning point,' says Chardan
- 06/10/21 William Blair
- Acer's increased pipeline visibility is encouraging, says William Blair
- 05/17/21 BTIG
- Adicet Bio initiated with a Buy at BTIG
- 05/17/21 BTIG
- Adicet Bio initiated with a Buy at BTIG
- 04/29/21
- Fly Intel: Top five analyst initiations
- 04/29/21 JonesTrading
- Adicet Bio initiated with a Buy at JonesTrading
- 08/02/21 Alliance Global Partners
- Cinedigm price target raised to $3.25 from $3.00 at Alliance Global Partners
- 05/12/21 Alliance Global Partners
- Alliance Global Partners bullish on Cinedigm, sees Roku among catalysts
- 01/21/21 Alliance Global Partners
- Cinedigm price target raised to $3 from $2 at Alliance Global Partners
- 10/16/20 Alliance Global Partners
- Cinedigm initiated with a Buy at Alliance Global Partners
- 04/06/21 Oppenheimer
- Opco starts 'attractive micro-cap play' Titan Medical with Outperform
- 04/06/21 Oppenheimer
- Titan Medical initiated with an Outperform at Oppenheimer
- 05/27/21 H.C. Wainwright
- Super League Gaming initiated with a Buy at H.C. Wainwright
- 03/01/21 Maxim
- Super League Gaming initiated with a Buy at Maxim
- 03/01/21 Maxim
- Super League Gaming initiated with a Buy at Maxim
- 02/09/21 Alliance Global Partners
- Super League downgraded on 'rich' valuation at Alliance Global
SLRX Salarius Pharmaceuticals - 08/25/21
- Fly Intel: Top five analyst initiations
- 08/25/21 H.C. Wainwright
- Salarius Pharmaceuticals initiated with a Buy at H.C. Wainwright
- 05/04/21 B. Riley
- Semler Scientific price target raised to $151 from $147 at B. Riley
- 04/27/21 B. Riley
- Semler Scientific transferred with Buy, $147 target at B. Riley
- 03/02/21 B. Riley
- Semler Scientific price target raised to $147 from $121 at B. Riley Securities
- 02/25/21 B. Riley
- Semler Scientific price target raised to $121 from $100 at B. Riley Securities
- 06/25/21 Alliance Global Partners
- Cannabis selloff brings buying opportunities, says Alliance Global
- 05/06/21 Cantor Fitzgerald
- Zynerba price target raised to $8 from $6 at Cantor Fitzgerald
- 03/29/21 Stifel
- Stifel says New York adult use cannabis market represents $5B opportunity
- 03/10/21 Roth Capital
- Zynerba price target lowered to $7.25 from $8.00 at Roth Capital
TARA Protara Therapeutics - 06/04/21 H.C. Wainwright
- Protara Therapeutics initiated with a Buy at H.C. Wainwright
- 04/26/21 Oppenheimer
- Protara Therapeutics price target lowered to $32 from $43 at Oppenheimer
- 10/19/20 Cowen
- Protara Therapeutics initiated with an Outperform at Cowen
TCON Tracon Pharmaceuticals - 06/04/21
- Fly Intel: Top five analyst initiations
- 06/04/21 Alliance Global Partners
- Tracon Pharmaceuticals initiated with a Buy at Alliance Global Partners
- 04/16/21 BTIG
- BTIG upgrades Tracon to Buy with $14 target on Envafolimab progress
- 04/16/21 BTIG
- Tracon Pharmaceuticals upgraded to Buy from Neutral at BTIG
- 03/15/21 H.C. Wainwright
- Rubius Therapeutics price target raised to $40 from $28 at H.C. Wainwright
- 10/14/20 JPMorgan
- Rubius Therapeutics resumed with a Neutral at JPMorgan
- 07/26/21 Stephens
- Pulse Biosciences a 'compelling and durable story,' says Stephens
- 07/26/21 Stephens
- Pulse Biosciences initiated with an Overweight at Stephens
- 03/11/21 Maxim
- Pulse Biosciences initiated with a Buy at Maxim
- 03/11/21 Maxim
- Pulse Biosciences initiated with a Buy at Maxim
- 07/29/21 Cowen
- Cowen starts Point Biopharma at Outperform
- 07/29/21 Cowen
- Point Biopharma initiated with an Outperform at Cowen
- 07/27/21 Jefferies
- Point Biopharma initiated with a Hold at Jefferies
- 07/26/21 Piper Sandler
- Point Biopharma initiated with an Overweight at Piper Sandler
- 08/11/21 Morgan Stanley
- Imara downgraded to Equal Weight from Overweight at Morgan Stanley
- 08/11/21 Morgan Stanley
- Imara downgraded to Equal Weight from Overweight at Morgan Stanley
- 03/08/21 SVB Leerink
- Imara price target lowered to $42 from $59 at SVB Leerink
- 01/06/21 SVB Leerink
- Imara selloff a potential buying opportunity, says SVB Leerink
- 09/03/21 Cantor Fitzgerald
- Cantor Fitzgerald positive on I-Mab following 'solid' first half
- 09/01/21 H.C. Wainwright
- I-Mab price target raised to $95 from $75 at H.C. Wainwright
- 07/26/21 Cantor Fitzgerald
- I-Mab's overdone weakness a buying opportunity, says Cantor Fitzgerald
- 07/13/21 Cantor Fitzgerald
- I-Mab price target raised to $95 from $90 at Cantor Fitzgerald
- 08/17/21 Maxim
- Kubient price target lowered to $9 from $13 at Maxim
- 03/26/21 Maxim
- Kubient price target raised to $13 from $10 at Maxim
- 10/27/20 Maxim
- Kubient initiated with a Buy at Maxim
- 09/13/21 Raymond James
- Leap Therapeutics price target raised to $4 from $3 at Raymond James
- 09/13/21 Piper Sandler
- Leap combo sees 'strong' early response rate, says Piper Sandler
- 06/03/21 Baird
- Leap Therapeutics transferred with Outperform at Baird
- 05/17/21 Piper Sandler
- Leap Therapeutics price target lowered to $4 from $6 at Piper Sandler
- 08/05/21 Piper Sandler
- Lumos shares trading below cash, says Piper Sandler
- 07/22/21 Roth Capital
- Lumos Pharma price target lowered to $35 from $51 at Roth Capital
- 07/21/21 Piper Sandler
- Piper says Lumos Pharma's OraGrowtH210 trial delay 'not a problem'
- 07/21/21 H.C. Wainwright
- Lumos Pharma price target lowered to $27 from $34 at H.C. Wainwright
- 12/07/20 BofA
- Lyra Therapeutics price target raised to $26 from $19 at BofA
- 04/28/21
- Fly Intel: Top five analyst initiations
- 04/28/21 Piper Sandler
- EDAP TMS initiated with an Overweight at Piper Sandler
- 04/01/21 H.C. Wainwright
- EDAP TMS price target raised to $12 from $10 at H.C. Wainwright
- 01/25/21 Lake Street
- EDAP TMS initiated with a Buy at Lake Street
- 08/06/21 H.C. Wainwright
- Exelixis price target raised to $64 from $35 at H.C. Wainwright
- 06/29/21 H.C. Wainwright
- Exelixis price target lowered to $35 from $47 at H.C. Wainwright
- 06/29/21 Oppenheimer
- Exelixis price target lowered to $27 from $35 at Oppenheimer
- 06/28/21 Piper Sandler
- Exelixis selloff on trial miss an overreaction, says Piper Sandler
- 06/23/21 Stifel
- Gemini's negative stock reaction to GEM103 data overdone, says Stifel
- 04/08/21 SVB Leerink
- SVB Leerink bullish on Gemini Therapeutics, initiates with an Outperform
- 04/08/21 SVB Leerink
- Gemini Therapeutics initiated with an Outperform at SVB Leerink
- 03/03/21 Jefferies
- Gemini Therapeutics initiated with a Buy at Jefferies
- 09/14/21 BTIG
- Bellus Health price target raised to $13 from $9 at BTIG
- 09/14/21 H.C. Wainwright
- Bellus Health price target raised to $14 from $10 at H.C. Wainwright
- 07/29/21 BTIG
- Bellus Health initiated with a Buy at BTIG
- 01/29/21 RBC Capital
- Bellus Health initiated with an Outperform at RBC Capital
CGRN Capstone Green Energy DYAI Dyadic International AGRI AgriFORCE Growing Systems ANEB Anebulo Pharmaceuticals - 05/25/21 Benchmark
- Anebulo Pharmaceuticals initiated with a Buy at Benchmark
- 01/29/21 Alliance Global Partners
- Viveve initiated with a Buy at Alliance Global Partners
- 08/10/21 Raymond James
- Ziopharm downgraded to Market Perform from Outperform at Raymond James
- 08/10/21 Lake Street
- Ziopharm price target lowered to $3.50 from $7 at Lake Street
- 08/10/21 Raymond James
- Ziopharm downgraded to Market Perform from Outperform at Raymond James
- 08/09/21 Raymond James
- Ziopharm downgraded to Market Perform from Outperform at Raymond James
- 08/09/21
- Zynerba reports Q2 EPS (25c), consensus (24c)
- 05/12/21
- Zynerba reports Q1 EPS (20c), consensus (25c)
TCON Tracon Pharmaceuticals - 08/11/21
- Tracon Pharmaceuticals reports Q2 EPS (58c,) consensus (31c)
- 05/05/21
- Tracon Pharmaceuticals reports Q1 EPS (33c), consensus (30c)
TARA Protara Therapeutics - 08/05/21
- Protara Therapeutics reports Q2 EPS ($1.14), consensus ($1.05)
- 05/06/21
- Protara Therapeutics reports Q1 EPS ($1.20), consensus (73c)
SLRX Salarius Pharmaceuticals - 08/05/21
- Salarius Pharmaceuticals reports Q2 EPS (7c), consensus (6c)
- 08/09/21
- Rubius Therapeutics reports Q2 EPS (56c), consensus (49c)
- 05/10/21
- Rubius Therapeutics reports Q1 EPS (51c), consensus (52c)
- 08/13/21
- Point Biopharma reports Q2 EPS (15c) vs. (7c) last year
- 05/10/21
- Pulse Biosciences reports Q1 EPS (71c), consensus (49c)
- 08/09/21
- Lyra Therapeutics reports Q2 EPS (85c), consensus (59c)
- 05/11/21
- Lyra Therapeutics reports Q1 EPS (60c), consensus (48c)
- 08/05/21
- Lumos Pharma reports Q2 EPS ($1.04), consensus ($1.04)
- 05/05/21
- Lumos Pharma reports Q1 EPS ($1.04), consensus (87c)
- 08/13/21
- Leap Therapeutics reports Q2 EPS (12c), consensus (12c)
- 05/14/21
- Leap Therapeutics reports Q1EPS (12c), consensus (11c)
- 08/16/21
- Kubient reports Q2 GAAP EPS (12c), one estimate (20c)
- 03/25/21
- Kubient reports Q4 EPS (28c), consensus (21c)
- 08/06/21
- Imara reports Q2 EPS (74c), consensus (8c)
- 05/11/21
- Imara reports Q1 EPS (58), two est. (83c)
- 08/12/21
- Gemini Therapeutics reports Q2 EPS (38c), consensus (40c)
- 08/05/21
- Exelixis sees FY21 revenue $1.3B-$1.4B, consensus $1.23B
- 08/05/21
- Exelixis reports Q2 adjusted EPS 37c, consensus 7c
- 05/06/21
- Exelixis reports Q1 EPS 9c, consensus 3c
- 08/25/21
- EDAP TMS reports Q2 EPS (2c), consensus 0c
- 08/04/21
- EDAP TMS reports preliminary Q2 revenue $12.4M, consensus $13.25M
- 03/30/21
- EDAP TMS reports Q4 EPS 3c, consensus 8c
- 09/02/21
- Cinedigm reports preliminary Q1 revenue $15M, one estimate $12.08M
- 07/30/21
- Cinedigm reports Q4 EPS (4c), two estimates (5c)
- 07/15/21
- Cinedigm reports Q4 preliminary revenue $8.3M vs. $7.7M last year
- 08/12/21
- Adicet Bio reports Q2 EPS (34c), consensus (53c)
- 05/17/21
- Adicet Bio reports Q1 EPS (82c), consensus (49c)
- 08/10/21
- Acer Therapeutics reports Q2 EPS (23c), consensus (36c)
- 05/17/21
- Acer Therapeutics reports Q1 EPS (11c), consensus (44c)
- 08/05/21
- Arbutus Biopharma reports Q2 EPS (23c), consensus (22c)
- 05/05/21
- Arbutus Biopharma reports Q1 EPS (21c), consensus (23)
|
|
Conference/Events
|
23rd Annual Global… 23rd Annual Global Investment Virtual Conference to be held on September 13-15.Webcast Link ShowHide Related Items >><< - 09/13/21
- Zynerba initiates RECONNECT Phase 3 trial of Zygel
- 09/09/21
- Zynerba presents data from Phase 2 BRIGHT trial for Zygel in children
- 09/07/21
- Zynerba announces publication of results of Phase 2 BELIEVE open-label study
- 08/09/21
- Zynerba sees cash, cash equivalents funding operations into H1 of 2024
- 08/30/21
- Ziopharm appoints Kevin Boyle as Chief Executive Officer, executive promotions
- 08/09/21
- Ziopharm closes ventured debt facility with Silicon Valley Bank for $50M
- 04/19/21
- Ziopharm announces first patient infused in CD19 RPM CAR-T Phase 1 trial
- 07/07/21
- Viveve announces new CPT code for its SUI procedure
- 04/01/21
- Viveve says TIPO issues patent for dual-energy technology device.
- 07/12/21
- Titan Medical appoints Stephen Lemieux as the CFO
- 05/28/21
- Titan Medical receives $10M license fee under Medtronic development agreement
- 05/24/21
- Titan Medical appoints Deepak Basra as VP, strategy and business development
TCON Tracon Pharmaceuticals - 08/09/21
- Tracon announce results of second IDMC review of ENVASARC
- 07/20/21
- Tracon appoints Brenda Marczi as SVP, regulatory affairs
- 06/30/21
- Tracon Pharmaceuticals announces appointment of Ya Huang as Executive Director
- 06/29/21
- Tracon Pharmaceuticals announces orphan drug designation for envafolimab
TARA Protara Therapeutics - 09/13/21
- Protara announces results from study on cholestasis in patients on PN
- 06/10/21
- Protara Therapeutics appoints Jane Huang to board of directors
- 04/23/21
- Protara to conduct additional clinical study for TARA-002 following FDA feedback
- 04/19/21
- Protara Therapeutics announces appointment of Olivo as Chief Medical Officer
SLRX Salarius Pharmaceuticals - 07/13/21
- Salarius adds Fox Chase Cancer Center to ongoing trial of seclidemstat
- 06/15/21
- Salarius Pharmaceuticals announces new clinical trial to study seclidemstat
- 06/07/21
- Salarius Pharmaceuticals presents research data on seclidemstat
- 09/13/21
- Super League Gaming, PRG form production partnership
- 08/12/21
- Super League Gaming established Young Gamer Network, Core Gamer Network
- 08/12/21
- Super League Gaming announces acquisition of Bannerfy
- 08/02/21
- Super League Gaming launches Pixel Paradise server
- 08/30/21
- Rubius Therapeutics appoints Jim Jogerst as CBO
- 08/09/21
- Rubius Therapeutics anticipated 2021 catalysts, objectives
- 07/29/21
- Rubius Therapeutics appoints Dannielle Appelhans as COO
- 07/15/21
- Rubius Therapeutics announces publication of RTX-240 preclinical data
- 09/14/21
- Point Biopharma and Convergent Therapeutics announce collaboration
- 07/21/21
- Point Biopharma, Isotopia announce Lutetium-177 clinical supply agreement
- 08/19/21
- Pulse Biosciences names Mitchell Levinson as Chief Strategy Officer
- 06/30/21
- Pulse Biosciences announces first CellFX procedure in Canada
- 06/09/21
- Pulse Biosciences announces Health Canada approval for CellFX System
- 09/13/21
- Lyra Therapeutics appoints Jason Cavalier as CFO
- 09/09/21
- Lyra Therapeutics announces preclinical XTreo data published
- 08/17/21
- Lyra Therapeutics to host virtual chronic thinosinusitis KOL event
- 06/30/21
- Lyra Therapeutics announce results of pharmacokinetic study of LYR-210
- 08/03/21
- Lumos Pharma announces David Karpf as Chief Medical Officer
- 08/02/21
- Lumos Pharma promotes John McKew to President
- 07/20/21
- Lumos Pharma provides clinical updates on OraGrowtH210, OraGrowtH212 trials
- 06/28/21
- Lumos Pharma announces OraGrowtH212 trial of LUM-201
- 09/13/21
- Leap Therapeutics announces DisTinGuish ORR data ahead of presentation
- 05/12/21
- Leap Therapeutics and Flagship Biosciences develop image analysis RNAscope assay
- 04/12/21
- Leap Therapeutics, Flagship Biosciences announce partnership
- 04/01/21
- Leap Therapeutics completes enrollment in first-line cohort of DKN-01 study
- 04/14/21
- Kubient appoints Leon Zemel as Chief Product Officer
- 08/06/21
- Imara sees cash, cash equivalents to fund operations through end of 2022
- 08/05/21
- Imara completes patient enrollment in Ardent Phase 2b trial of IMR-687
- 06/30/21
- Imara announce appointment of Laura Williams to board of directors
- 06/04/21
- Imara to present data on IMR-687 in SCD at EHA Annual Congress
- 08/11/21
- I-Mab's plonmarlimab shows positive results in severe COVID-19 treatment
- 07/30/21
- I-Mab's Protollin IND for Phase 1 study in Alzheimer's approved by FDA
- 07/29/21
- I-MAB announces new $40M stock repurchase program
- 07/28/21
- I-Mab: IND for Phase 2 trial of efineptakin alfa accepted by CDE of China
- 06/22/21
- Gemini reports initial data from ongoing Phase 2a study of GEM103
- 05/20/21
- NeuBase Therapeutics appoints Sandra Rojas-Caro as CMO
- 05/13/21
- Gemini Therapeutics completes enrollment in GEM103 trial
- 05/02/21
- Gemini Therapeutics presents preclinical data at ARVO
- 09/07/21
- Exelixis announces passing of Chief Medical Officer Gisela Schwab
- 08/25/21
- Exelixis partner Takeda and Ono get Japan approval for cabozantinib in RCC
- 08/16/21
- Exelixis, Invenra expand discovery and licensing collaboration by 20 targets
- 08/05/21
- Exelixis announces FDA acceptance of Cabometyx sNDA
- 09/14/21
- EDAP TMS announces multiple abstracts comparing HIFU to surgery
- 07/20/21
- EDAP TMS CEO says focused on expanding coverage for HIFU
- 06/15/21
- EDAP TMS announces appointment of Ryan Rhodes as CEO of company's subsidiary
- 03/29/21
- EDAP TMS trading resumes
DYAI Dyadic International - 08/11/21
- Sorrento, Dyadic enter binding term sheet for DYAI-100, C1 technology
- 08/11/21
- Dyadic, Sorrento announce binding term sheet to enter License Agreement
- 07/27/21
- Dyadic signs technology transfer, licensing agreement with Rubic Consortium
- 06/28/21
- Dyadic International C1 production platform utilized in ZAPI study
- 09/07/21
- Cinedigm says The Film Detective acquires Holland Releasing's film, TV library
- 09/02/21
- Cinedigm receives Nasdaq notice of deficiency
- 08/23/21
- Cinedigm expands partnership with All3Media International
- 07/30/21
- Cinedigm regains Nasdaq compliance
CGRN Capstone Green Energy - 09/10/21
- Capstone Green Energy distributor signs energy agreement
- 08/23/21
- Capstone Green Energy contracts remote data center in Louisiana
- 08/16/21
- Capstone Green Energy completes expansion at UK facility
- 07/28/21
- Capstone Green Energy wins multiple deals with wastewater treatment plants
- 09/13/21
- Bellus Health announces positive findings in SOOTHE trial of BLU-5937 in RCC
AGRI AgriFORCE Growing Systems - 09/09/21
- AgriFORCE Growing Systems signs MOU for product deployment in Barbados
- 07/22/21
- AgriFORCE appoints Troy McClellan as president, AgriFORCE Solutions
- 07/14/21
- AgriFORCE Growing Systems appoints Richard Levychin to board
- 07/13/21
- AgriFORCE Growing Systems appoints Amy Griffith to board of directors
- 09/13/21
- Twist, Adicet Bio enter collaboration to discover gamma delta T cell therapies
- 09/13/21
- Adicet Bio collaborates with Twist to accelerate cancer therapeutics
- 07/15/21
- Adicet Bio announces formation of Scientifc Advisory Board
- 06/28/21
- Adicet Bio added to Russell 2000 Index
- 08/09/21
- Acer Therapeutics, Relief announce submission of NDA to FDA for ACER-001
- 06/10/21
- Acer Therapeutics plans trial for EDSIVO following Type B FDA meeting
- 05/25/21
- Acer Therapeutics plans NDA submission of ACER-001 in Q3
- 03/22/21
- Acer Therapeutics and Relief in pact and licensing agreement for ACER-001
- 08/17/21
- Arbutus Biopharma up 7% as Forbes details background of COVID-19 vaccine tech
- 08/05/21
- Arbutus Biopharma expects cash to fund operations into Q3 of 2022
- 07/07/21
- Arbutus Biopharma receives authorization to proceed with AB-729 IND application
- 07/06/21
- Arbutus Biopharma and Vaccitech enter into trial collaboration agreement
- 06/28/21 JMP Securities
- Arbutus EASL updates still support progress in Chronic HBV, says JMP Securities
- 03/10/21 B. Riley
- Arbutus Biopharma price target lowered to $7 from $8 at B. Riley Securities
- 12/17/20 H.C. Wainwright
- Arbutus Biopharma initiated with a Buy at H.C. Wainwright
- 09/15/20 Chardan
- Arbutus HBV data 'could represent a turning point,' says Chardan
- 06/10/21 William Blair
- Acer's increased pipeline visibility is encouraging, says William Blair
- 05/17/21 BTIG
- Adicet Bio initiated with a Buy at BTIG
- 05/17/21 BTIG
- Adicet Bio initiated with a Buy at BTIG
- 04/29/21
- Fly Intel: Top five analyst initiations
- 04/29/21 JonesTrading
- Adicet Bio initiated with a Buy at JonesTrading
- 08/02/21 Alliance Global Partners
- Cinedigm price target raised to $3.25 from $3.00 at Alliance Global Partners
- 05/12/21 Alliance Global Partners
- Alliance Global Partners bullish on Cinedigm, sees Roku among catalysts
- 01/21/21 Alliance Global Partners
- Cinedigm price target raised to $3 from $2 at Alliance Global Partners
- 10/16/20 Alliance Global Partners
- Cinedigm initiated with a Buy at Alliance Global Partners
- 04/06/21 Oppenheimer
- Opco starts 'attractive micro-cap play' Titan Medical with Outperform
- 04/06/21 Oppenheimer
- Titan Medical initiated with an Outperform at Oppenheimer
- 05/27/21 H.C. Wainwright
- Super League Gaming initiated with a Buy at H.C. Wainwright
- 03/01/21 Maxim
- Super League Gaming initiated with a Buy at Maxim
- 03/01/21 Maxim
- Super League Gaming initiated with a Buy at Maxim
- 02/09/21 Alliance Global Partners
- Super League downgraded on 'rich' valuation at Alliance Global
SLRX Salarius Pharmaceuticals - 08/25/21
- Fly Intel: Top five analyst initiations
- 08/25/21 H.C. Wainwright
- Salarius Pharmaceuticals initiated with a Buy at H.C. Wainwright
- 05/04/21 B. Riley
- Semler Scientific price target raised to $151 from $147 at B. Riley
- 04/27/21 B. Riley
- Semler Scientific transferred with Buy, $147 target at B. Riley
- 03/02/21 B. Riley
- Semler Scientific price target raised to $147 from $121 at B. Riley Securities
- 02/25/21 B. Riley
- Semler Scientific price target raised to $121 from $100 at B. Riley Securities
- 06/25/21 Alliance Global Partners
- Cannabis selloff brings buying opportunities, says Alliance Global
- 05/06/21 Cantor Fitzgerald
- Zynerba price target raised to $8 from $6 at Cantor Fitzgerald
- 03/29/21 Stifel
- Stifel says New York adult use cannabis market represents $5B opportunity
- 03/10/21 Roth Capital
- Zynerba price target lowered to $7.25 from $8.00 at Roth Capital
TARA Protara Therapeutics - 06/04/21 H.C. Wainwright
- Protara Therapeutics initiated with a Buy at H.C. Wainwright
- 04/26/21 Oppenheimer
- Protara Therapeutics price target lowered to $32 from $43 at Oppenheimer
- 10/19/20 Cowen
- Protara Therapeutics initiated with an Outperform at Cowen
TCON Tracon Pharmaceuticals - 06/04/21
- Fly Intel: Top five analyst initiations
- 06/04/21 Alliance Global Partners
- Tracon Pharmaceuticals initiated with a Buy at Alliance Global Partners
- 04/16/21 BTIG
- BTIG upgrades Tracon to Buy with $14 target on Envafolimab progress
- 04/16/21 BTIG
- Tracon Pharmaceuticals upgraded to Buy from Neutral at BTIG
- 03/15/21 H.C. Wainwright
- Rubius Therapeutics price target raised to $40 from $28 at H.C. Wainwright
- 10/14/20 JPMorgan
- Rubius Therapeutics resumed with a Neutral at JPMorgan
- 07/26/21 Stephens
- Pulse Biosciences a 'compelling and durable story,' says Stephens
- 07/26/21 Stephens
- Pulse Biosciences initiated with an Overweight at Stephens
- 03/11/21 Maxim
- Pulse Biosciences initiated with a Buy at Maxim
- 03/11/21 Maxim
- Pulse Biosciences initiated with a Buy at Maxim
- 07/29/21 Cowen
- Cowen starts Point Biopharma at Outperform
- 07/29/21 Cowen
- Point Biopharma initiated with an Outperform at Cowen
- 07/27/21 Jefferies
- Point Biopharma initiated with a Hold at Jefferies
- 07/26/21 Piper Sandler
- Point Biopharma initiated with an Overweight at Piper Sandler
- 08/11/21 Morgan Stanley
- Imara downgraded to Equal Weight from Overweight at Morgan Stanley
- 08/11/21 Morgan Stanley
- Imara downgraded to Equal Weight from Overweight at Morgan Stanley
- 03/08/21 SVB Leerink
- Imara price target lowered to $42 from $59 at SVB Leerink
- 01/06/21 SVB Leerink
- Imara selloff a potential buying opportunity, says SVB Leerink
- 09/03/21 Cantor Fitzgerald
- Cantor Fitzgerald positive on I-Mab following 'solid' first half
- 09/01/21 H.C. Wainwright
- I-Mab price target raised to $95 from $75 at H.C. Wainwright
- 07/26/21 Cantor Fitzgerald
- I-Mab's overdone weakness a buying opportunity, says Cantor Fitzgerald
- 07/13/21 Cantor Fitzgerald
- I-Mab price target raised to $95 from $90 at Cantor Fitzgerald
- 08/17/21 Maxim
- Kubient price target lowered to $9 from $13 at Maxim
- 03/26/21 Maxim
- Kubient price target raised to $13 from $10 at Maxim
- 10/27/20 Maxim
- Kubient initiated with a Buy at Maxim
- 09/13/21 Raymond James
- Leap Therapeutics price target raised to $4 from $3 at Raymond James
- 09/13/21 Piper Sandler
- Leap combo sees 'strong' early response rate, says Piper Sandler
- 06/03/21 Baird
- Leap Therapeutics transferred with Outperform at Baird
- 05/17/21 Piper Sandler
- Leap Therapeutics price target lowered to $4 from $6 at Piper Sandler
- 08/05/21 Piper Sandler
- Lumos shares trading below cash, says Piper Sandler
- 07/22/21 Roth Capital
- Lumos Pharma price target lowered to $35 from $51 at Roth Capital
- 07/21/21 Piper Sandler
- Piper says Lumos Pharma's OraGrowtH210 trial delay 'not a problem'
- 07/21/21 H.C. Wainwright
- Lumos Pharma price target lowered to $27 from $34 at H.C. Wainwright
- 12/07/20 BofA
- Lyra Therapeutics price target raised to $26 from $19 at BofA
- 04/28/21
- Fly Intel: Top five analyst initiations
- 04/28/21 Piper Sandler
- EDAP TMS initiated with an Overweight at Piper Sandler
- 04/01/21 H.C. Wainwright
- EDAP TMS price target raised to $12 from $10 at H.C. Wainwright
- 01/25/21 Lake Street
- EDAP TMS initiated with a Buy at Lake Street
- 08/06/21 H.C. Wainwright
- Exelixis price target raised to $64 from $35 at H.C. Wainwright
- 06/29/21 H.C. Wainwright
- Exelixis price target lowered to $35 from $47 at H.C. Wainwright
- 06/29/21 Oppenheimer
- Exelixis price target lowered to $27 from $35 at Oppenheimer
- 06/28/21 Piper Sandler
- Exelixis selloff on trial miss an overreaction, says Piper Sandler
- 06/23/21 Stifel
- Gemini's negative stock reaction to GEM103 data overdone, says Stifel
- 04/08/21 SVB Leerink
- SVB Leerink bullish on Gemini Therapeutics, initiates with an Outperform
- 04/08/21 SVB Leerink
- Gemini Therapeutics initiated with an Outperform at SVB Leerink
- 03/03/21 Jefferies
- Gemini Therapeutics initiated with a Buy at Jefferies
- 09/14/21 BTIG
- Bellus Health price target raised to $13 from $9 at BTIG
- 09/14/21 H.C. Wainwright
- Bellus Health price target raised to $14 from $10 at H.C. Wainwright
- 07/29/21 BTIG
- Bellus Health initiated with a Buy at BTIG
- 01/29/21 RBC Capital
- Bellus Health initiated with an Outperform at RBC Capital
CGRN Capstone Green Energy DYAI Dyadic International AGRI AgriFORCE Growing Systems ANEB Anebulo Pharmaceuticals - 05/25/21 Benchmark
- Anebulo Pharmaceuticals initiated with a Buy at Benchmark
- 01/29/21 Alliance Global Partners
- Viveve initiated with a Buy at Alliance Global Partners
- 08/10/21 Raymond James
- Ziopharm downgraded to Market Perform from Outperform at Raymond James
- 08/10/21 Lake Street
- Ziopharm price target lowered to $3.50 from $7 at Lake Street
- 08/10/21 Raymond James
- Ziopharm downgraded to Market Perform from Outperform at Raymond James
- 08/09/21 Raymond James
- Ziopharm downgraded to Market Perform from Outperform at Raymond James
- 08/09/21
- Zynerba reports Q2 EPS (25c), consensus (24c)
- 05/12/21
- Zynerba reports Q1 EPS (20c), consensus (25c)
TCON Tracon Pharmaceuticals - 08/11/21
- Tracon Pharmaceuticals reports Q2 EPS (58c,) consensus (31c)
- 05/05/21
- Tracon Pharmaceuticals reports Q1 EPS (33c), consensus (30c)
TARA Protara Therapeutics - 08/05/21
- Protara Therapeutics reports Q2 EPS ($1.14), consensus ($1.05)
- 05/06/21
- Protara Therapeutics reports Q1 EPS ($1.20), consensus (73c)
SLRX Salarius Pharmaceuticals - 08/05/21
- Salarius Pharmaceuticals reports Q2 EPS (7c), consensus (6c)
- 08/09/21
- Rubius Therapeutics reports Q2 EPS (56c), consensus (49c)
- 05/10/21
- Rubius Therapeutics reports Q1 EPS (51c), consensus (52c)
- 08/13/21
- Point Biopharma reports Q2 EPS (15c) vs. (7c) last year
- 05/10/21
- Pulse Biosciences reports Q1 EPS (71c), consensus (49c)
- 08/09/21
- Lyra Therapeutics reports Q2 EPS (85c), consensus (59c)
- 05/11/21
- Lyra Therapeutics reports Q1 EPS (60c), consensus (48c)
- 08/05/21
- Lumos Pharma reports Q2 EPS ($1.04), consensus ($1.04)
- 05/05/21
- Lumos Pharma reports Q1 EPS ($1.04), consensus (87c)
- 08/13/21
- Leap Therapeutics reports Q2 EPS (12c), consensus (12c)
- 05/14/21
- Leap Therapeutics reports Q1EPS (12c), consensus (11c)
- 08/16/21
- Kubient reports Q2 GAAP EPS (12c), one estimate (20c)
- 03/25/21
- Kubient reports Q4 EPS (28c), consensus (21c)
- 08/06/21
- Imara reports Q2 EPS (74c), consensus (8c)
- 05/11/21
- Imara reports Q1 EPS (58), two est. (83c)
- 08/12/21
- Gemini Therapeutics reports Q2 EPS (38c), consensus (40c)
- 08/05/21
- Exelixis sees FY21 revenue $1.3B-$1.4B, consensus $1.23B
- 08/05/21
- Exelixis reports Q2 adjusted EPS 37c, consensus 7c
- 05/06/21
- Exelixis reports Q1 EPS 9c, consensus 3c
- 08/25/21
- EDAP TMS reports Q2 EPS (2c), consensus 0c
- 08/04/21
- EDAP TMS reports preliminary Q2 revenue $12.4M, consensus $13.25M
- 03/30/21
- EDAP TMS reports Q4 EPS 3c, consensus 8c
- 09/02/21
- Cinedigm reports preliminary Q1 revenue $15M, one estimate $12.08M
- 07/30/21
- Cinedigm reports Q4 EPS (4c), two estimates (5c)
- 07/15/21
- Cinedigm reports Q4 preliminary revenue $8.3M vs. $7.7M last year
- 08/12/21
- Adicet Bio reports Q2 EPS (34c), consensus (53c)
- 05/17/21
- Adicet Bio reports Q1 EPS (82c), consensus (49c)
- 08/10/21
- Acer Therapeutics reports Q2 EPS (23c), consensus (36c)
- 05/17/21
- Acer Therapeutics reports Q1 EPS (11c), consensus (44c)
- 08/05/21
- Arbutus Biopharma reports Q2 EPS (23c), consensus (22c)
- 05/05/21
- Arbutus Biopharma reports Q1 EPS (21c), consensus (23)
|
|
Recommendations
|
Maxim analyst Jack Vander… Maxim analyst Jack Vander Aarde lowered the firm's price target on Kubient to $9 from $13 but keeps a Buy rating on the shares. The company's Q2 revenue missed his estimates due to longer-than-anticipated sales cycles, though these headwinds are likely to be "temporary" and due to the early-stage company's smaller scale and limited resources on-hand, the analyst tells investors in a research note. Vander Aarde adds that the stock currently trades at 1.9-times enterprise value to expected 2023 revenue multiple - below the 6.5-times peer valuation - and his new price target model a 5.5-times multiple. ShowHide Related Items >><< - 04/14/21
- Kubient appoints Leon Zemel as Chief Product Officer
- 03/26/21 Maxim
- Kubient price target raised to $13 from $10 at Maxim
- 10/27/20 Maxim
- Kubient initiated with a Buy at Maxim
- 08/16/21
- Kubient reports Q2 GAAP EPS (12c), one estimate (20c)
- 03/25/21
- Kubient reports Q4 EPS (28c), consensus (21c)
|
|
Earnings
|
Reports Q2 revenue… Reports Q2 revenue $498,000, one estimate $800,000. As of June 30, the company had a cash balance of approximately $30.5M. ShowHide Related Items >><< - 04/14/21
- Kubient appoints Leon Zemel as Chief Product Officer
- 03/26/21 Maxim
- Kubient price target raised to $13 from $10 at Maxim
- 10/27/20 Maxim
- Kubient initiated with a Buy at Maxim
- 03/25/21
- Kubient reports Q4 EPS (28c), consensus (21c)
|
